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ABSTRACT 25 
Background 26 
Cancer-associated Þbroblasts (CAFs) are known to impact on tumour behaviour but mechanisms 27 
controlling this are poorly understood.  28 
Methods 29 
Breast normal fibroblasts (NFs) or CAFs were isolated from cancers by laser-microdissection or 30 
were cultured. Fibroblasts were transfected to manipulate miR-222 or Lamin B Receptor (LBR). 31 
Fibroblast conditioned medium was collected and used to treat epithelial BC lines MDA-MB-32 
231 and MDA-MB-157. Migration, invasion, proliferation, or senescence was assessed using 33 
transwell, MTT or X-gal assays respectively.  34 
Results 35 
MiR-222 was up-regulated in CAFs as compared to NFs. Ectopic miR-222 expression in NFs 36 
induced CAF-like expression profiles, while miR-222 knock-down in CAFs inhibited CAF 37 
phenotypes. LBR was identified as a direct miR-222 target and was functionally relevant since 38 
LBR knock-down phenocopied miR-222 over-expression and LBR over-expression phenocopied 39 
miR-222 knock-down. MiR-222 over-expression, or LBR knock-down, was sufficient to induce 40 
NFs to show CAF characteristics of enhanced migration, invasion and senescence, and 41 
furthermore conditioned medium from these fibroblasts induced increased BC cell migration and 42 
invasion. The reverse manipulations in CAFs inhibited these behaviours in fibroblasts and 43 
inhibited paracrine influences on BC cells. 44 
Conclusion 45 
MiR-222/LBR have key roles in controlling pro-progression influences of CAFs in BC. This 46 
pathway may present therapeutic opportunities to inhibit CAF-induced cancer progression.  47 
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BACKGROUND 48 
Breast cancer (BC) is the leading cause of cancer death worldwide among women1, and nearly 49 
2.3 million females are newly diagnosed annually2. Although there are initial responses to 50 
treatment, many cancers relapse and distant metastases occur in nearly one third of woman; these 51 
are typically fatal3. The biology behind BC metastases still remains undetermined. Therefore, 52 
understanding molecular determinants of metastasis is crucial for finding new therapeutic 53 
strategies. The tumour microenvironment consists of immune cells, blood vessels, endothelial 54 
cells, fibroblasts and extracellular matrix4. This microenvironment plays key roles in disease 55 
outcome by inducing tumour cell proliferation and aggressiveness5,6. Cancer-associated 56 
Þbroblasts (CAFs), an activated form of tissue-resident fibroblasts present within breast cancers, 57 
comprise a major component of the tumour microenvironment7, characterised most commonly 58 
by expression of Į-smooth muscle actin8. CAFs can induce cancer progression9 and metastasis10 59 
by secreting various cytokines, chemokines and growth factors (e.g. VEGF, FGF2, TGFȕ, 60 
CXCL12, IL6 and IL8)11,12 and by modulating the extracellular matrix (ECM) that facilitates 61 
tumour cell migration and invasion13,14. CAFs also modulate immune cell function to create an 62 
immune suppressive environment during cancer progression15. The process of transformation of 63 
CAFs from resident normal Þbroblasts is achieved by several growth factors16,17,18, however 64 
mechanisms of transformation have not yet been fully explored and may represent attractive 65 
targets for therapeutic intervention; interestingly, once transformed into CAFs, the CAF 66 
phenotype has been regarded as stable, probably though maintenance of epigenetic changes19.  67 
 68 
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression by binding to 69 
the 3untranslated regions (3UTRs) of target genes, leading to post-transcriptional down-70 
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regulation20. MiRNAs can be oncogenic or act as tumour suppressors, depending upon the 71 
specific genes that they regulate21,22. Dysregulation of miRNAs within the fibroblast component 72 
of breast cancer has been reported, and is therefore implicated in induction or maintenance of the 73 
CAF phenotype. For example, differential expression between breast CAFs and normal 74 
fibroblasts has been reported for many miRNAs, including miR-221, miR-31, miR-205, miR-75 
200b, miR-200c, miR-107, miR-30b, the let-7 family and miR-26b23,24, although there is 76 
relatively little consistency between reports. Far fewer miRNAs have been shown experimentally 77 
to have functional impacts on the breast CAF phenotype, or most interestingly indirectly on 78 
cancer cell behaviour; examples include miR-26b24, let-7b25, miR-200 family26 and miR-29b27. 79 
Although some of these studies have indicated functional roles for specific miRNAs within 80 
CAFs, very few studies have directly investigated miRNA roles on the transformation and 81 
maintenance of CAF phenotypes and on how this impacts on cancer behaviour, therefore how 82 
miRNAs in CAFs are involved in cancer progression remains poorly understood. Here, we have 83 
focussed on miR-222 as a candidate regulator of CAF phenotypes and cancer behaviour. MiR-84 
222 has previously been reported as an oncogenic miRNA in various cancers including BC28-32, 85 
functioning within the cancer cells themselves, as opposed to stromal cells. Furthermore, it has 86 
been shown that up-regulation of miR-222 induced growth of cancer cells by targeting 87 
p27/kip132, as well as chemoresistance by targeting PTEN/Akt33. Interestingly, in the context of 88 
our study on function in fibroblasts, levels of miR-222 positively correlated with fibroblast 89 
viability in hypertrophic scar tissues34, while miR-222 has been shown to induce replicative 90 
senescence in human lung fibroblasts35. However, to date, no studies have been published on 91 
roles of miR-222 in CAFs. Therefore, the above observations suggest the importance of miR-222 92 
as a post-transcriptional modifier, playing functional roles in BC progression. However, it is 93 
 5 
 
unclear whether expression of miR-222 is only tumour cell specific or the other cells also 94 
express miR-222 in tumour microenvironment. As miR-222 is an important oncogenic factor in 95 
breast cancer we wanted to unveil whether CAFs also expressed miR-222 to influence disease 96 
progression.    97 
 98 
MATERIALS AND METHODS 99 
Reagents 100 
Foetal bovine serum (FBS), DMEM and antibiotic/antimycotic (100X; 10,000units/mL 101 
penicillin, 10,000µg/mL streptomycin, 25µg/mL Amphotericin B) were purchased from 102 
ThermoFisher (MA, USA). Antibodies for Į-smooth muscle actin (ab5694), LBR (ab32535) and 103 
ȕ-Actin (ab8227) were purchased from Abcam (MA, USA), and for Vimentin (#5741S) and Slug 104 
(#9585S) from Cell Signaling Technology (MA, USA). Secondary anti-rabbit antibody was 105 
purchased from Bangalore Genei (Bangalore, India). AlexaFluor 488-conjugated anti-rabbit and 106 
TRITC-conjugated anti-rabbit antibodies were purchased from ThermoFisher (MA, USA). MiR-107 
222-3p mimics (#MSY0000279) and inhibitors (#MIN0000279), miScript inhibitor negative 108 
control (#1027271), siLBR (#SI00035798) and AllStars negative control siRNA (#1027280) 109 
were purchased from Qiagen (Hilden, Germany). Lipofectamine 3000 was purchased from 110 
ThermoFisher (MA, USA). ȕ-Galactosidase assay kit was purchased from Cell Signaling 111 
Technology (MA, USA). KpnI, XbaI, PmeI, NotI and T4 DNA ligase were purchased from New 112 
England Biolabs (MA, USA). 113 
 114 
Ethical issues, and cell culture  115 
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Ethical approval for collection and use of human tissue was obtained from the Leeds East REC 116 
(references 06/Q1206/180, 09/H1306/108), and also from the Ethical Committee, Medical 117 
College, Kolkata, references MC/KOL/IEC/NON-SPON/102/09-2015. Fresh samples of 118 
surgically removed breast cancer samples were minced, digested with collagenase IV from 119 
HiMedia Laboratories Pvt. Ltd (Mumbai, India), and plated (collagenase I coated) to derive 120 
primary breast CAFs (from within tumour masses) and NFs (from >1cm outside tumour 121 
margins). Breast cancer cell lines MDA-MB-231 and MDA-MB-157 were obtained from the 122 
ATCC (VA, USA). The NF and CAF Þbroblast lines were derived from breast cancer samples 123 
and immortalised using lentiviral transduction of hTERT, as previously described24. All cell lines 124 
were cultured in DMEM with 10% FBS and 1% antibiotics/antimycotics in a humid atmosphere 125 
incubator with 5% CO2 at 37°C. NFs were transfected with scrambled siRNA negative control 126 
(NC), siLBR, miR-222 mimic or mimic control using Lipofectamine 3000 (ThermoFisher; MA, 127 
USA) according to manufacturers instruction. Similarly, CAFs were transfected with scramble 128 
negative control, miR-222 inhibitor, pCDNA or pCDNA-LBR. 72h after transfection, cells were 129 
harvested for Western blotting, qRT-PCR analyses, senescence studies or migration/invasion 130 
studies. To collect NF and CAF conditioned medium, cells were seeded into 6-well plates at 131 
1.5x105 cells/well. As previously described, cells were transfected as appropriate for 24h, then 132 
medium was replaced with fresh DMEM. After 48h and 72h of incubation medium was collected 133 
and centrifuged at 150g for 5min then the supernatant was collected. 134 
 135 
RNA isolation and qPCR 136 
For LMD samples, total RNA was extracted from using RecoverAll Total Nucleic Acid Isolation 137 
Kit for FFPE (ThermoFisher; MA, USA) following the manufacturers protocols, or the 138 
 7 
 
mirVanaTM miRNA Isolation Kit (ThermoFisher; MA, USA). RNA was reverse-transcribed for 139 
miR-222 using the TaqMan MicroRNA RT kit (ThermoFisher; MA, USA) and the resulting first 140 
strand was amplified using specific Taqman miRNA assay primers (ThermoFisher; MA, USA). 141 
The PCRs were performed by StepOne plus detection system (ThermoFisher; MA, USA), and 142 
amplification data were normalised using RNU6 expression. Relative expression levels were 143 
calculated using the 2ǻǻCt method. For cultured primary fibroblasts (in Figure 1B), RNA was 144 
isolated from a 90-mm dish of cultured cells using TRIzol (ThermoFisher; MA, USA), according 145 
to manufacturer instruction and RNA quantified by MULTISCANGO (ThermoFisher; MA, 146 
USA). For miRNA expression status and gene expression status, first strand cDNA and cDNA 147 
were synthesised with miScript RT-II kit (Qiagen, Hilden, Germany) and Superscript III 148 
(ThermoFisher; MA, USA) respectively. MiR-222 expression was analysed using PCR starter 149 
kits (Qiagen, Hilden, Germany); U6 was used as an endogenous control. Quantitative RT-PCR 150 
was performed using the Power SYBR Green Master Mix (ThermoFisher; MA, USA) on 151 
StepOne detection system (ThermoFisher; MA, USA). Expression was normalised to the house-152 
keeping gene 18S. 153 
 154 
Protein extraction and Western blots 155 
Cells were washed with PBS and lysed in RIPA lysis buffer System (lysis buffer pH 7.4, 200mM 156 
PMSF, protease inhibitor cocktail, 100mM sodium orthovanadate) (SantaCruz-sc24948). The 157 
lysates were centrifuged at 12700g for 20min at 4ûC. Protein concentrations were determined 158 
using BCA Protein Assay Kit (ThermoFisher; MA, USA).  Total protein was separated by SDS-159 
PAGE (12% gel) then transferred to PVDF membranes (Millipore) and blocked with 5% 160 
skimmed milk. Membrane were then incubated overnight with primary antibodies. Protein bands 161 
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were detected by incubation with horseradish peroxidase (HRP)-conjugated antibodies 162 
(Bangalore Genei, Bangalore, India). Bands were visualised using ECL. 163 
 164 
Histology, laser capture microdissection (LMD) and immunohistochemistry (IHC) 165 
LMD was carried out on the Zeiss PALM Laser Capture Microdissection Microscope exactly as 166 
described previously24. In brief, archival FFPE cancer blocks and matched normal blocks were 167 
obtained and sectioned at 10ȝm onto Membrane Slides NF 1.0 PEN (Zeiss; Oberkochen, 168 
Germany). A guide section was stained with haematoxylin and eosin and reviewed by a 169 
histopathologist (LMW) to identify areas of fibroblasts with very few admixed inflammatory 170 
cells, epithelial cells or necrosis. The equivalent areas were then identified on other sections and 171 
these were collected with the laser into lids of AdhesiveCap500 opaque PCR Tubes (Zeiss; 172 
Oberkochen, Germany) by laser pressure catapulting (LPC). The microscope settings used for 173 
LCM were cut energy 71, focus 65, LPC energy 100, focus 65 at 100x magnification. Areas 174 
dissected from each case varied between 5.2-27.4x106ȝm2 depending on fibroblast density. For 175 
IHC, FFPE human breast cancer resection tissue was available; cancerous and non-cancerous 176 
breast tissue was immunostained for Į-SMA and LBR.  The signal was amplified and visualised 177 
with 3, 3-diaminobenzidine (DAB) chromogen, followed by counterstaining with haematoxylin.   178 
 179 
Luciferase reporter assays 180 
The potential miR-222 binding sequence from the LBR gene (WT LBR) and 3 nucleotide 181 
mutated LBR (MUT LBR) (Fig 2A) were cloned into pMiRGLO (Promega, WI, USA) under 182 
restriction sites PmeI and XbaI (primers listed in Table S1). Luciferase activities were measured 183 
48h after transfection using Dual-Luciferase Reporter Assays (Promega, WI, USA).   184 
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 185 
Cell proliferation assays 186 
NFs and CAFs were seeded in 96-well plates at 1x104 cells/well and transfected the following 187 
day. Cell proliferation was monitored after 72h by MTT (HiMedia Laboratories, Mumbai, India). 188 
10µl MTT solution (10mg/ml) in 100µl of DMEM media was added per well. After 4h of 189 
incubation, formazan complexes were dissolved in 100µl DMSO and signals were measured 190 
using MULTISCANGO plate reader (ThermoFisher; MA, USA). To evaluate effects of 191 
conditioned media, MDA-MB-231 and MDA-MB-157 were seeded in 96-well plates at 2x104 192 
cells/well. 24h after seeding condition media was applied. MTT assays were performed at 48h as 193 
above. 194 
 195 
Cell migration and invasion assays  196 
Cell migration and invasion ability was determined by Corning transwell insert chambers (8µm 197 
pores; Corning, MA, USA) and Matrigel (Sigma Aldrich, MO, USA) coated in transwell 198 
chamber for invasion analysis. Conditional media from different treatment conditions were used 199 
in lower chambers for migration and invasion study. The cells were prior treated with conditional 200 
media for 48h. 1x105 cells of MDA-MB-231 or MDA-MB-157 were added into chambers and 201 
incubated for 28h at 37ºC. Cells that had migrated or invaded were fixed with 100% methanol, 202 
stained with 0.5% crystal violet, imaged and counted manually. 203 
 204 
Senescence-associated beta-galactosidase (SA-ß-gal) assays  205 
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SA-ß-gal activity was detected by ß-gal staining kit (Cell Signaling Technologies) according to 206 
the manufacturer's instructions. Cells containing blue stain were counted manually as positive 207 
senescent cells, and images were taken under phase contrast. 208 
 209 
Cell immunostaining and confocal microscopy 210 
NFs and CAFs were allowed to attach to glass coverslips overnight at 37ûC. Cells were fixed in 211 
4% paraformaldehyde (20min) and permeabilised with 0.1% Triton X-100 (15min). Blocking 212 
was performed with 5% BSA for 1h followed by incubation with Į-SMA and Vimentin primary 213 
antibodies (4ûC overnight). Alexa Fluor 488-conjugated and TRITC-conjugated secondary 214 
antibodies were incubated for 1h. Coverslips were counterstained with DAPI and analysed on 215 
confocal microscope (Olympus). 216 
 217 
Cloning 218 
For LBR overexpressing vector, LBR open reading frame was cloned within pCDNA 3.1+ 219 
vector using KpnI and XbaI restriction sites and primers 220 
GTGGTACCACCATGCCAAGTAGGAAATTTG (forward) and 221 
GCTCTAGAGCTTAGTAGATGTATGGAAATATACGG (reverse). 222 
 223 
Statistical analyses 224 
All data are representative of at least three independent experiments. Results are presented as 225 
means +/- SEM of at least three independent experiments in all the figures. Differences were 226 
considered statistically signiÞcant at p<0.05 using Students t-test.  227 
 228 
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RESULTS 229 
 230 
miR-222 is up-regulated in breast CAFs, and controls CAF phenotypes 231 
Many studies have shown that miRNAs are dysregulated in CAFs. To investigate roles of miR-232 
222 dysregulation in CAF biology, we first assessed relative expression of miR-222 in 14 233 
matched pairs of normal fibroblasts (NFs) and cancer associated fibroblasts (CAFs) that have 234 
been isolated from breast cancer resection samples using laser micro-dissection (LMD). We 235 
found miR-222 to be up-regulated in CAFs relative to matched NFs in 11 out of 14 cases, 236 
representing significant up-regulation overall by a mean fold of 3.63 (p<0.04; Fig.1A, left plot). 237 
To expand this finding, we further assessed miR-222 expression in 4 matched pairs of primary 238 
human breast NFs and CAFs cultures extracted from breast cancer resections; we found a greater 239 
than 2-fold induction of miR-222 in CAFs as compared to matched NFs in all cases (Fig.1A, 240 
middle plot). Finally, miR-222 expression in immortalised human breast NFs was compared to 241 
immortalised human breast CAFs; this also showed higher expression of miR-222 in CAFs by 242 
more than 3-fold (Fig.1A, right plot). We concluded that miR-222 is more highly expressed in 243 
CAFs than NFs in breast tissue. 244 
To explore functional roles of miR-222 in transformation of NFs to CAFs, we conducted a series 245 
of experiments on immortalised human breast NFs or immortalised human breast CAFs using 246 
miR-222 mimics to up-regulate expression in NFs, or miR-222 inhibitors to downregulate 247 
expression in CAFs. First, miR-222 expression was assessed using qRT-PCR to confirm 248 
appropriate over- or under-expression (Fig.1B); miR-222 was significantly over-expressed by 249 
more than 8-fold and was knocked down to one third of its original level. Next, the relatively 250 
normal or CAF-like phenotypes of these cell lines were characterised to establish their base-251 
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lines for subsequent analyses. Expression of a range of classical CAF markers7,8,12 was assessed 252 
using qRT-PCR (Fig.1C), immunofluorescence or western blotting (Fig.S1). Relative 253 
expressions of ACTA2 (smooth muscle actin), FSP, CCL2 and VEGF were all substantially 254 
higher in CAFs as compared to NFs (a minimum of 5-fold higher as assessed by qRT-PCR), as 255 
indicative of the CAF phenotype. Up-regulation in CAFs of ACTA2/smooth muscle actin and 256 
vimentin was also confirmed at the protein level (Fig.S1). Next, NFs were transfected with miR-257 
222 mimics, or control mimics, and CAFs were transfected with miR-222 inhibitors or control 258 
inhibitors, and miR-222s influence on transformation of NFs to CAFs, or on maintenance of the 259 
CAF phenotype was examined using the same panel of CAF markers as previously. Transfection 260 
of miR-222 mimics in NFs resulted in significant up-regulation of all the CAF markers (qRT-261 
PCR, Fig.1D, left plot; Western blots, Fig.1E). Furthermore, downregulation of miR-222 in 262 
CAFs using miR-222 inhibitors significantly down-regulated expression of the CAF markers, 263 
with the notable and surprising exception of CCL2 (qRT-PCR, Fig.1D, right plot; Western blots, 264 
Fig.1E). We concluded that miR-222 levels play key roles in controlling the CAF phenotype in 265 
breast fibroblasts. 266 
 267 
LBR is a direct target of miR-222  268 
To investigate potential mechanisms by which miR-222 plays roles in breast fibroblast biology, 269 
bioinformatics tools were used to predict potential target genes of miR-222. We analysed the 270 
best possible miR-222 seed matches using miRanda, TargetScan, and miRDB software. 11 271 
predicted target genes were chosen for further analysis based on the target scores, containing 272 
seed matches for miR-222. On analysis of expression by qRT-PCR in NFs and paired CAFs from 273 
patient samples three of these genes, RECK, THOP1 and LBR, demonstrated differential 274 
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expression in the predicted direction. LBR showed the most substantial and consistent 275 
dysregulated result in NFs and CAFs and therefore LBR was prioritised for subsequent analyses. 276 
The potential miR-222 binding site within the LBR 3UTR is depicted in Fig.2A. We performed 277 
a number of different assays to assess whether LBR is a true direct target of miR-222 within 278 
breast fibroblasts. First, luciferase reporter constructs containing either the wild-type miR-222 279 
binding site from the LBR 3UTR or a mutated (non-binding) version of the site (Fig.2A) were 280 
cloned. Reporters were co-transfected with miR-222 mimics and inhibitors, or appropriate 281 
controls, in NFs and CAFs respectively, and luciferase assays were performed. MiR-222 mimics 282 
significantly inhibited the activity of the luciferase reporter containing the wild-type LBR site, 283 
while the mutated site was insensitive to miR-222 over-expression in NFs (Fig.2B, left plot), 284 
whereas miR-222 inhibitors significantly increased the activity of the wild-type reporter, while 285 
the mutated reporter was again insensitive in CAFs (Fig.2B, right plot). Next, endogenous LBR 286 
expression was assessed in NFs after transfection to over-express miR-222, and in CAFs after 287 
transfection with miR-222 inhibitors (Fig.2C and D). LBR expression was down-regulated by 288 
miR-222 over-expression and upregulated by miR-222 inhibition at the level of both transcript 289 
(Fig.2C) and protein (Fig.2D), findings that were in accordance with it being down-stream of 290 
miR-222 function. We concluded that LBR is a direct target of miR-222 in breast fibroblasts, via 291 
a canonical miR-222 binding site within the LBR 3UTR. 292 
 293 
Down-regulation of LBR induces a CAF-like phenotype 294 
Our next aim was to determine whether LBR down-regulation is involved in determining the 295 
breast CAF phenotype, since we have already determined that CAFs over-express miR-222 and 296 
that this can down-regulate LBR. In one approach, we examined whether breast normal stroma 297 
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or tumour stroma exhibit differential expression of LBR using immunohistochemistry. LBR 298 
expression(Fig.2E), was relatively reduced in tumour stroma, in contrast to ACTA2 (smooth 299 
muscle actin) (Fig.S2) which was relatively high in tumour stroma. In addition, qRT-PCR was 300 
performed on 8 matched pairs of primary NF and CAF cultures. LBR expression was 301 
significantly reduced by a mean of 4.3-fold in CAFs compared to the NFs (p<0.01), in contrast to 302 
expression of the CAF markers ACTA2 and vimentin, which were up-regulated in CAFs as 303 
expected and indicative of the CAF phenotype (Fig.2F and G).  304 
We next assessed whether LBR down-regulation was sufficient for transformation of NFs to 305 
CAFs, and conversely whether LBR over-expression would reduce CAF features. We transfected 306 
immortalised breast NFs with siRNA targeted against LBR or with an appropriate non-targeting 307 
control, and also transfected immortalised breast CAFs with plasmids to allow over-expression 308 
of LBR, or with appropriate control plasmids. The efficacy of knock-down and overexpression 309 
was confirmed using qRT-PCR (Fig.3A) and Western blots (Fig.3B); knock-down was to 310 
approximately 30% of the original levels, while overexpression was by more than 9-fold. Next, 311 
we assessed expression of our panel of CAF markers in these cells after knock-down or over-312 
expression of LBR using qRT-PCR or Western blots as previously. Reduction of LBR 313 
expression in NFs, and increased expression of LBR in CAFs, significantly increased and 314 
decreased respectively expression of all the CAF markers (Fig.3C-E). We concluded that LBR is 315 
a key regulator of the breast CAF phenotype, and that knock-down of LBR alone is sufficient to 316 
transform NFs into cells that resemble CAFs. 317 
 318 
MiR-222 and LBR regulate migration, invasion and senescence in breast fibroblasts 319 
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Since it has been previously demonstrated that CAFs are characterised by higher cell motility 320 
than their adjacent NFs36, we also investigated whether miR-222 overexpression or siRNA 321 
mediated knock-down of LBR would induce increased NF migration or invasion, and conversely 322 
whether miR-222 inhibition or LBR over-expression would reduce CAF migration or invasion. 323 
Immortalised breast NFs or CAFs were transfected as previously with miR-222 mimics or 324 
inhibitors respectively, or with siRNA targeted against LBR or overexpression of LBR 325 
respectively. We then performed migration or invasion assays using transwell assays. NFs 326 
transfected with miR-222 mimics or siRNA targeting LBR had significantly higher migration 327 
and invasion capacity (Fig.4A, B, left plots), whereas inhibition of miR-222 or LBR over-328 
expression in CAFs significantly reduced their migration and invasion capacity (Fig.4A, B right 329 
plots). In order to confirm that these apparent effects on migration and invasion did not relate to 330 
differences in cell numbers induced by the transfections, we also evaluated proliferation 331 
capabilities of fibroblasts after these manipulations of miR-222 or LBR expression. We 332 
performed MTT assays after the same transfected conditions as mentioned above; there were no 333 
significant differences in proliferation of NFs or CAFs after any of these treatments (Fig.S3). We 334 
concluded that miR-222 and its target LBR have key influences on aspects of CAF-like 335 
fibroblast behaviour, namely migration and invasion. 336 
It was previously reported that loss of LBR is associated with induction of cellular senescence37, 337 
therefore, we also specifically evaluated senescence by determining senescence associated ȕ 338 
galactosidase (SA- ȕ-gal) activities in NFs and CAFs after dysregulation of expression of miR-339 
222 or LBR. We found an increased SA-ȕ-gal activity in NFs transfected with miR-222 mimics 340 
or siLBR compared to controls (Fig.4C, left plot). In addition, inhibition of miR-222 activity or 341 
increased LBR expression in CAFs significantly reduced SA-ȕ-gal activity (Fig.4C, right plot). 342 
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We also further examined features of this senescence phenotype by determining whether it was 343 
also associated with differential expression of other senescence markers. NFs and CAFs were 344 
transfected as before, and qRT-PCR was used to assess expression of MMP3, OPN ,IL6 and IL8, 345 
which are upregulated in senescent cells particularly those showing the senescence associated 346 
secretory phenotype (SASP)38,39. Expression of all four markers was significantly up-regulated in 347 
NFs transfected with miR-222 mimic or siLBR (Fig.4D, left plot), while expression was 348 
significantly down-regulated in CAFs transfected with miR-222 inhibitors or to over-express 349 
LBR (Fig.4D, right plot). This provided strong support that changes in ȕ-gal activity we had 350 
detected were indeed associated with senescence, and that miR-222 and LBR expression impact 351 
on senescence phenotypes in breast fibroblasts.  352 
 353 
miR-222 and LBR in breast fibroblasts regulate proliferation, migration and invasion of 354 
cancer cells 355 
To better understand the exact effects of miR-222 and its action on LBR in fibroblasts on 356 
epithelial breast cancer cell behaviour, we assessed abilities of NFs and CAFs after manipulation 357 
of miR-222 or LBR expression to induce growth or migration/invasion of breast cancer cells. In 358 
particular, we focused on the highly metastatic MDA-MB-231 and the relatively less metastatic 359 
and triple negative MDA-MB-157 cell lines. In order to assess influences of fibroblasts on the 360 
cancer cells, we decided to collect conditioned medium from fibroblasts and treat cancer cells 361 
with this. Fibroblast-conditioned medium has frequently been shown to influence cancer cell 362 
behaviour in this context36. NFs or CAFs were transfected exactly as previously. Conditional 363 
medium (CM) was collected from these cells after transfection and was added to cultures of 364 
epithelial breast cancer cells. First, proliferation of epithelial cells was assessed using MTT 365 
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assays after treatment with CM (Fig.5A, B). In both epithelial cell lines, CM from control NFs 366 
caused a marginal, but not significant, reduction in proliferation, while CM from control CAFs 367 
caused a marked and significant increase in proliferation when compared to cells without CM 368 
(p<0.005), as has been reported previously36. More interestingly, over-expression of miR-222 in 369 
NFs and knock-down of miR-222 in CAFs significantly altered the activity of these CMs on both 370 
epithelial cell lines; miR-222 over-expression in NFs produced CM that had similar growth 371 
inducing effects to that from control CAFs, while knock-down of miR-222 in CAFs reduced this 372 
growth stimulation (Fig.5A). Changes in LBR expression within NFs and CAFs also had similar 373 
significant effects, with LBR knock-down allowing CM from NFs to induce relative growth 374 
increases, while over-expression of LBR in CAFs reduced the growth stimulatory effect of CAF 375 
CM (Fig.5B). We concluded that up-regulation of miR-222 and down-regulation of LBR were 376 
both necessary and sufficient for CAF function with respect to inducing proliferation of breast 377 
cancer cells. Next, we investigated the influences of these CMs on the motility of BC cells. BC 378 
cells also responded dramatically and significantly to these CMs in terms of migration and 379 
invasion capacities. CM from NFs had little influence on migration, while CM from CAFs 380 
significant and consistently induced migration (Fig.5 C, E) and invasion (Fig.5 D, F) in both 381 
epithelial cell lines. Over-expression of miR-222 or knock-down of LBR in NFs led to enhanced 382 
migration in the epithelial lines. Knock-down of miR-222 or over-expression of LBR in CAFs 383 
led to reduced migration in the epithelial lines. Exactly the same result was evident in terms of 384 
invasion, with miR-222 and LBR having a key influence on abilities of NFs or CAFs to induce 385 
invasion in both epithelial cell lines (Fig.5 C, D, E, F). To further clarify that differences in 386 
migration/invasion of the breast cancer epithelial cells treated with CM did not solely relate to 387 
changes in proliferation rate, we additionally performed an experiment assessing proliferation in 388 
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the cells treated exactly as for the migration/invasion assay (Fig.S4), which involves an earlier 389 
time-point than that used for Fig.5 A, B. There were no significant differences in almost all 390 
combinations, supporting the conclusion that true differences in migration/invasion were seen. 391 
An exception is MDA-MB-157 cells treated with CAF CM, in which a significant reduction in 392 
proliferation was seen with CM after miR-222 knock-down and LBR over-expression; however, 393 
this change in proliferation was only up to 20% (Fig.S4), whereas decreases in 394 
migration/invasion were up to 50% (Fig.5E,F), indicating that  again  true influences on 395 
migration/invasion were seen. 396 
  397 
Finally, to determine whether the fibroblasts were influencing migration and invasion capacity of 398 
epithelial cells by inducing epithelial to mesenchymal transition (EMT) pathways, we analysed 399 
expression of EMT markers slug and vimentin in the BC cells after culture with the same CMs, 400 
using both qRT-PCR and Western blots (Fig.6). CM from NFs had little influence on slug or 401 
vimentin expression at either transcript or protein level, while CM from CAFs induced up to a 6-402 
fold increase in expression. Manipulation of miR-222 or LBR expression in the fibroblasts 403 
consistently and significantly altered slug and vimentin expression in accordance with the 404 
changes in migration and invasion, with greater slug and vimentin expression in cells induced to 405 
migrate/invade more by miR-222 mimics or LBR siRNA in NFs, and reduced slug and vimentin 406 
expression in cells induced to migrate/invade less by miR-222 inhibition or LBR over-expression 407 
in CAFs. We concluded that miR-222 and, down-stream of this, LBR have key influences on 408 
abilities of breast fibroblasts to control critical cancer-related behaviours of breast epithelial 409 
cancer cells, including proliferation, migration, invasion and EMT. 410 
 411 
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 412 
DISCUSSION 413 
Increasing evidence supports the proposal that miRNA dysregulation within CAFs modulates 414 
function of the tumour microenvironment. However, it is worth highlighting that most studies 415 
have emphasised investigation of miRNA roles within the tumour cells themselves, therefore it 416 
remains the case that relatively little is known about roles of miRNAs in the tumour 417 
microenvironment. In this study, we have focussed on roles of miR-222 within fibroblasts.  418 
 419 
We initially compared the miR-222 expression difference between CAFs and adjacent NFs in 420 
breast cancer tissue samples. Our study demonstrated that miR-222 was significantly up-421 
regulated in CAFs. Although others have made similar comparisons for multiple miRNAs in this 422 
context23,24,26,40, miR-222 has not previously been identified as differentially expressed. This may 423 
be because studies have not always effectively purified only the fibroblasts for their analyses, as 424 
we have by LMD, or may be because miR-222 was not always included in the analyses. Next, 425 
we identified that miR-222 targets Lamin B receptor (LBR) expression in the CAFs. Various 426 
targets of miR-222 have been published previously, but LBR is a novel target on which we 427 
focused since we were able to confirm its down-regulation in CAFs in accordance with negative 428 
regulation by the up-regulated miR-222. Most importantly, down-regulation of LBR with siRNA 429 
phenocopied miR-222 over-expression in functional experiments using breast fibroblasts, 430 
strongly suggesting that LBR is a key functionally-important target of miR-222 in these cells.  431 
In terms of cellular function, we showed that miR-222 and LBR were both involved in defining 432 
and maintaining the breast CAF phenotype in terms of expression patterns, and fibroblast 433 
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behaviours including migration and invasion. MiR-222 has previously been assigned roles in 434 
promotion of cell proliferation, migration, invasion and drug resistance within cancer cells32,33,41, 435 
so our findings are in accordance with this, although they represent the first observations to our 436 
knowledge in a cancer stromal cell type. With respect to functions of LBR, a role in senescence 437 
has previously been reported in fibroblasts37 and we also observed a related result with 438 
manipulation of LBR expression by siRNA, over-expression or via miR-222 all impacting on 439 
senescence in breast fibroblasts. LBR encodes the lamin B receptor, a 70.4 kD protein of the 440 
inner nuclear membrane42, which is known to interact with heterochromatin and B-type lamins43. 441 
Other functions for the protein have been implied by observations that ectopic LBR expression 442 
deregulates differentiation of olfactory neurons inducing an un- or early-differentiated state44. 443 
 444 
More excitingly, we showed that fibroblasts with differential expression of miR-222 or LBR 445 
have potent differential influences on behaviour of two independent breast epithelial cancer cell 446 
lines. We demonstrated that conditioned medium from fibroblasts that were stimulated to be 447 
more CAF-like by miR-222 over-expression or siLBR promoted breast cancer proliferation, 448 
migration and invasion. Similarly, abilities of conditioned medium from CAFs to promote breast 449 
cancer proliferation, migration and invasion was inhibited by reduced miR-222 levels or by LBR 450 
over-expression. Next, we investigated possible pathways involved in the breast tumour motility 451 
effects. We found that the enhanced migration and invasion was associated with increased 452 
expression of vimentin and slug in the BC cells, suggesting involvement of the EMT pathway. 453 
Taken together, these results suggest that miR-222 up-regulation, and subsequent LBR down-454 
regulation, within fibroblasts in the tumour microenvironment contribute to progression of BC, 455 
through induction of proliferation and EMT-related motility. It is established that cancer 456 
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progression is not only dependent on tumour cells themselves but also dependent on the tumour 457 
microenvironment45,46 and, in particular, CAFs, which promote growth and invasion of cancer 458 
cells through synthesis and remodelling of ECM and secreting some growth factors47,48. Hence, 459 
blocking CAF activity may be a key approach to effectively control cancer metastasis. 460 
Manipulation of either miR-222 expression or LBR function provide candidate approaches for 461 
development of these types of anti-cancer therapies.  In particular, our data demonstrate that 462 
reduced expression of miR-222 or over-expression of LBR in CAFs greatly reduces their ability 463 
to promote aggressive behaviours in cancer cells, supporting the proposal that CAF phenotypes 464 
are not fixed and could be normalised therapeutically. 465 
 466 
Surprisingly, our data also implicate the miR-222/LBR axis in senescence induction in CAFs. 467 
Previous studies have indicated that increased miR-222 or loss of LBR induces senescence49,50, 468 
so this is not a surprise in itself, however it is unexpected that high levels of senescence in CAFs 469 
would be associated with cancer cell behaviours that promote progression, since senescence is 470 
often regarded as a tumour suppressor mechanism in cancer cells51. However, more recent 471 
evidence shows that senescence cells may promote oncogenesis through secretion of secretory 472 
factors (SASP)38 and several reports describe abilities of senescent human fibroblasts to promote 473 
growth and tumorigenesis39. In support of this, here, we demonstrated that miR-222 474 
overexpression in NFs induces a SASP phenotype, leading to increased secretion of, at least, the 475 
SASP factors IL6, IL8, and the classical senescence marker MMP3.  476 
 477 
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In conclusion, we present miR-222 and LBR as key molecules involved in transformation and 478 
maintenance of breast CAFs, which in turn therefore impacts on the aggressive tumorigenic 479 
behaviour of breast cancer cells. These molecules are novel targets for therapeutic intervention. 480 
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FIGURE LEGENDS 640 
Figure 1: MiR-222 is upregulated in breast cancer associated fibroblasts (CAFs), and 641 
controls breast fibroblast phenotype. A) MiR-222 expression was determined by qPCR and is 642 
shown for CAFs relative to NFs in 3 separate cell types. Left plot: matched pairs of normal 643 
fibroblasts (NFs) and CAFs were isolated from breast cancer patient samples using laser micro-644 
dissection of archival (fixed) tissue. Data represent technical triplicates. Middle plot: 4 matched 645 
pairs of primary cultured CAFs and NFs from breast cancer patient derived tumour samples. 646 
Data represent technical triplicates. Right plot: immortalised breast CAF and NF cell lines. Data 647 
represent biological triplicates. B) Immortalised breast NFs (left) or CAFs (right) were 648 
transfected with miR-222 mimics or control (NC), or miR-222 inhibitor (i) or control (NC) and 649 
miR-222 expression was assessed using qPCR. Data represent biological triplicates. C) Relative 650 
gene expression levels of the CAF markers, Į-SMA, Fibroblast Specific Protein (FSP), CCL2 651 
and VEGF were assessed in immortalised CAFs as compared to immortalised NFs using qPCR. 652 
Data represent biological triplicates. D) Relative expression levels of the same CAF markers 653 
were assessed using qPCR in NFs (left) or CAFs (right) transfected with miR-222 mimics or 654 
control (NC), or miR-222 inhibitor (i) or control (NC). Data represent biological triplicates. E) 655 
NFs or CAFs were transfected with miR-222 mimics or control (NC), or miR-222 inhibitor (i) or 656 
control (NC) and protein expression of the CAF markers Į-SMA (ACTA2) and Vimentin were 657 
assessed using Western blots, along with ȕ-Actin as a loading control.  p<0.0005(***) and 658 
p<0.005(**)   659 
Figure 2: Lamin B Receptor (LBR) is a direct target of miR-222 in breast fibroblasts and is 660 
downregulated in breast CAFs relative to matched NFs. A) LBR was identified as a potential 661 
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miR-222 target by bioinformatics. The potential miR-222 binding site within the LBR 3-UTR is 662 
shown (WT), along with a binding-dead mutant used experimentally (MUT). B) Luciferase 663 
reporters were cloned that allow expression of luciferase transcripts containing the wild type or 664 
mutant LBR miR-222 3UTR binding sites. These were transfected into NFs (left) or CAFs 665 
(right) along with either miR-222 mimic or control (NC), or miR-222 inhibitor (i) or control 666 
(NC), and relative luciferase activity was determined. Data represent two biological replicates. C 667 
and D) NFs or CAFs were transfected as shown and relative expression of endogenous LBR was 668 
determined using qPCR (C) or Western blots (D). qPCR data represent three biological 669 
replicates. E) Representative matched pair of normal and breast cancer tissues was assessed for 670 
expression of LBR by immunohistochemistry (10X and 20X magnification). Brown staining 671 
represents expression of the target protein, while pink is a counter-stain. F) Relative expression 672 
of LBR was assessed in 8 pairs of primary cultured NFs and CAFs isolated from breast cancer 673 
patient derived tumour.  Data represent technical triplicates. G) Protein expression levels of 674 
LBR, and the CAF markers Į-SMA and Vimentin were assessed by Western blotting in 3 pairs 675 
of primary cultured NFs and CAFs isolated from breast cancer patient derived tumour samples. 676 
ȕ-Actin was used as a loading control.  p<0.0005(***), p< 0.005(**), p< 0.05(*) 677 
Figure 3: LBR regulates the NF vs CAF breast fibroblast phenotype. A and B) Immortalised 678 
breast NFs (left) or CAFs (right) were transfected with siRNA targeting LBR (siLBR) or control 679 
(NC), or plasmid to allow over-expression of LBR (LBR OE) or control plasmid (pCDNA), and 680 
LBR expression was assessed using qPCR (A) or Western blots (B). qPCR data represent 681 
biological triplicates, while ȕ-Actin represents a loading control for the Western analysis. C, D 682 
and E) Immortalised breast NFs (C and E) or CAFs (D and E) were transfected as shown and 683 
relative expression levels of the CAF marker genes Į-SMA, Fibroblast Specific Protein (FSP), 684 
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CCL2 and VEGF was determined by qPCR (C and D), or of Į-SMA and Vimentin by Western 685 
blot (E). qPCR data represent biological triplicates, while ȕ-Actin represents a loading control 686 
for the Western analysis. p< 0.0005(***) and p< 0.005(**) 687 
Figure 4: MiR-222 and its down-stream target LBR modulate the behaviour of breast 688 
fibroblasts. Immortalised breast NFs were transfected with miR-222 mimic or siRNA targeting 689 
LBR (siLBR) or appropriate controls (NC), and immortalised breast CAFs were transfected with 690 
miR-222 inhibitor (i) or to over-express LBR (LBR OE) or with appropriate controls (NC, 691 
pCDNA). A,B) Migration (A) or invasion (B) of fibroblasts was assessed using transwell assays. 692 
Representative images are shown (A, B-Upper panels), along with quantified data that represent 693 
biological triplicates (A, B- Lower panels).  C) Expression of senescence-associated ȕ-694 
galactosidase was also assessed by X-gal staining and is shown as blue green colouration (Upper 695 
panels). Positive cells were quantified in data that represent biological triplicates (Lower panels). 696 
D) Expression of the senescence markers MMP3 and Osteopontin (OPN), and senescence 697 
associated secretory phenotype markers IL6 and IL8 were assessed by qPCR in NFs (Left plot) 698 
and CAFs (Right plot). Data represent biological triplicates. p< 0.0005(***), p<0.005(**), 699 
p<0.05(*).  700 
Figure 5: MiR-222 and LBR control the ability of breast fibroblasts to influence cancer cell 701 
proliferation and metastatic potential. Immortalised breast NFs were transfected with miR-702 
222 mimic or siRNA targeting LBR (siLBR) or appropriate controls (NC), and immortalised 703 
breast CAFs were transfected with miR-222 inhibitor (i) or to over-express LBR (LBR OE) or 704 
with appropriate controls (NC, pCDNA). Conditioned medium (CM) was collected from 705 
fibroblast cultures and used to treat breast epithelial cancer lines MDA-MB-231 or MDA-MB-706 
157. A and B) Proliferation of MDA-MB-231 or MDA-MB-157 cell lines cultured with 707 
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conditioned medium (CM) from the transfected fibroblasts as labelled was determined using 708 
MTT assay. Data represent biological triplicates. C-F) Migration (C, E) or invasion (D, F) of 709 
epithelial cancer cells was assessed using transwell assays. Representative images are shown 710 
(Upper panels), along with quantified data that represent biological triplicates (Lower panels). 711 
p<0.0005(***), p<0.005(**), p<0.05(*) 712 
Figure 6: MiR-222 and LBR control the ability of breast fibroblasts to activate EMT in 713 
breast cancer cells. Immortalised breast NFs were transfected with miR-222 mimic or siRNA 714 
targeting LBR (siLBR) or appropriate controls (NC), and immortalised breast CAFs were 715 
transfected with miR-222 inhibitor (i) or to over-express LBR (LBR OE) or with appropriate 716 
controls (NC, pCDNA). Conditioned medium (CM) was collected from fibroblast cultures and 717 
used to treat breast epithelial cancer lines MDA-MB-231 or MDA-MB-157. Expression levels of 718 
the EMT-associated genes Slug and Vimentin were assessed in MDA-MB-231 or MDA-MB-157 719 
cell lines cultured with conditioned medium (CM) from the transfected fibroblasts as labelled 720 
using qPCR (A and C) or Western blots (B and D). qPCR data represent biological triplicates, 721 
while ȕ-Actin represents a loading control for the Western analysis. p<0.0005(***), 722 
p<0.005(**), p<0.05(*) 723 






